Age Related Macular Degeneration - Pipeline Review, Q2 2011 by GlobalMarketsDirect

VIEWS: 5 PAGES: 114

Age Related Macular Degeneration - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Age Related Macular Degeneration - Pipeline Review, Q2 2011', provides an overview of the Age Related Macular Degeneration therapeutic pipeline. This report provides information on the therapeutic development for Age Related Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Age Related Macular Degeneration. 'Age Related Macular Degeneration - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Age Related Macular Degeneration.
- A review of the Age Related Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Age Related Macular Degeneration pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse

More Info
									Age Related Macular Degeneration – Pipeline Review, Q2 2011




  Age Related Macular Degeneration - Pipeline Review,
                       Q2 2011
                                                                                          Reference Code: GMDHC1073IDB

                                                                                          Publication Date: April 2011




Age Related Macular Degeneration – Pipeline Review, Q2 2011                                                              GMDHC1073IDB / Pub April 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied
                                                                                                                                               Page(1)
Age Related Macular Degeneration – Pipeline Review, Q2 2011



Ta b le o f Co n te n ts
Table of Contents                                                                                                                 2
List of Tables                                                                                                                    6
List of Figures                                                                                                                   9
Introduction                                                                                                                     10
     Global Markets Direct Report Coverage                                                                                       10
Age Related Macular Degeneration Overview                                                                                        11
Therapeutics Development                                                                                                         12
     An Overview of Pipeline Products for Age Related Macular Degeneration                                                       12
Age Related Macular Degeneration Therapeutics under Development by Companies                                                     14
Age Related Macular Degeneration Therapeutics under Investigation by Universities/Institutes                                     19
Late Stage Products                                                                                                              22
     Comparative Analysis                                                                                                        22
Mid Clinical Stage Products                                                                                                      23
     Comparative Analysis                                                                                                        23
Early Clinical Stage Products                                                                                                    24
     Comparative Analysis                                                                                                        24
Discovery and Pre-Clinical Stage Products                                                                                        25
     Comparative Analysis                                                                                                        25
Age Related Macular Degeneration Therapeutics - Products under Development by Companies                                          26
Age Related Macular Degeneration Therapeutics - Products under Investigation by Universities/Institutes                          34
Companies Involved in Age Related Macular Degeneration Therapeutics Development                                                  36
     Alcon, Inc.                                                                                                                 36
     Genzyme Corporation                                                                                                         36
     Johnson & Johnson                                                                                                           37
     F. Hoffmann-La Roche Ltd.                                                                                                   37
     Abbott Laboratories                                                                                                         38
     Allergan, Inc.                                                                                                              38
     QLT Inc.                                                                                                                    39
     Advanced Cell Technology, Inc.                                                                                              39
     GlaxoSmithKline plc                                                                                                         40
     Santen Pharmaceutical Co., Ltd.                                                                                             40
     Oxford BioMedica plc                                                                                                        41
     Lux Biosciences, Inc.                                                                                                       41
     Light Sciences Oncology, Inc.                                                                                               42
     Optherion, Inc.                                                                                                             42
     Novartis AG                                                                                                                 43
     Pfizer Inc.                                                                                                                 43
     VasGene Therapeutics, Inc.                                                                                                  44
     Shire Plc                                                                                                                   44
     ISTA Pharmaceuticals, Inc.                                                                                                  45
     Alchemia Limited                                                                                                            45
     iCo Therapeutics Inc.                                                                                                       46
     InNexus Biotechnology Inc.                                                                                                  46
     Lpath, Inc.                                                                                                                 47
     ReGenX Biosciences, LLC                                                                                                     47
     Ophthotech Corp.                                                                                                            48
     OXiGENE, Inc.                                                                                                               48


Age Related Macular Degeneration – Pipeline Review, Q2 2011                                               GMDHC1073IDB / Pub April 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                         Page(2)
Age Related Macular Degeneration – Pipeline Review, Q2 2011


     Alexion Pharmaceuticals, Inc.                                                                               49
     Regeneron Pharmaceuticals, Inc.                                                                             50
     Progen Pharmaceuticals Limited                                                                              50
     Sirion Therapeutics, Inc.                                                                                   51
     Summit Corporation plc                                                                                      51
     Sucampo Pharmaceuticals, Inc.                                                                               52
     ThromboGenics NV                                                                                            52
     Simcere Pharmaceutical Group                                                                                53
     PolyMedix, Inc.                                                                                             53
     e-Therapeutics plc                                                                                          54
     NanoCarrier Co., Ltd.                                                                                       54
     R-Tech Ueno, Ltd.                                                                                           55
     Paloma Pharmaceuticals, Inc.                                                                                55
     Digna Biotech, S.L.                                                                                         56
     Ceregene, Inc.                                                                                              56
     CoMentis, Inc.                                                                                              57
     StemCells, Inc.                                                                                             57
     Ora Bio Ltd.                                                                                                58
     Molecular Partners AG                                                                                       58
     Acucela Inc.                                                                                                59
     Acceleron Pharma, Inc.                                                                                      59
     Applied Genetic Technologies Corporation                                                                    60
     Neovacs SA                                                                                                  60
     Cosmix Molecular Biologicals GmbH                                                                           61
     MAT Biopharma                                                                                               61
     InCode BioPharmaceutics, Inc.                                                                               62
     OcuCure Therapeutics, Inc.                                                                                  62
     Neurotech Pharmaceuticals, Inc.                                                                             63
     Gene Signal International SA.                                                                               63
     Promedior, Inc.                                                                                             64
     Iconic Therapeutics, Inc.                                                                                   64
     Inotek Pharmaceuticals Corporation                                                                          65
     Indus Biotech Private Limited                                                                               65
     Othera Pharmaceuticals, Inc.                                                                                66
     Cardax Pharmaceuticals, Inc.                                                                                66
     NOXXON Pharma AG                                                                                            66
     Adeona Pharmaceuticals, Inc.                                                                                67
     Angstrom Pharmaceuticals, Inc.                                                                              67
     Alimera Sciences, Inc.                                                                                      68
     Taiwan Liposome Company                                                                                     68
     Biovista Inc.                                                                                               69
     Resolvyx Pharmaceuticals, Inc                                                                               69
     Allostera Pharma Inc.                                                                                       70
     Charlesson LLC.                                                                                             70
     KAI Pharmaceuticals Inc.                                                                                    71
     TaiGen Biotechnology Co., Ltd.                                                                              71
     Kemin Industries, Inc.                                                                                      72
     OHR Pharmaceutical Inc.                                                                                     72




Age Related Macular Degeneration – Pipeline Review, Q2 2011                               GMDHC1073IDB / Pub April 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                         Page(3)
Age Related Macular Degeneration – Pipeline Review, Q2 2011


     Steba Laboratories Ltd.                                                                                     73
Age Related Macular Degeneration - Therapeutics Assessment                                                       74
     Assessment by Monotherapy Products                                                                          74
     Assessment by Combination Products                                                                          75
     Assessment by Route of Administration                                                                       76
     Assessment by Molecule Type                                                                                 79
Drug Profiles                                                                                                    82
     VEGF Trap-Eye - Drug Profile                                                                                82
          Product Description                                                                                    82
          Mechanism of Action                                                                                    82
          R&D Progress                                                                                           82
     AL-8309B - Drug Profile                                                                                     84
          Product Description                                                                                    84
          Mechanism of Action                                                                                    84
          R&D Progress                                                                                           84
     Avastin - Drug Profile                                                                                      85
          Product Description                                                                                    85
          Mechanism of Action                                                                                    85
          R&D Progress                                                                                           85
     Lucentis + Visudyne - Drug Profile                                                                          86
          Product Description                                                                                    86
          Mechanism of Action                                                                                    86
          R&D Progress                                                                                           86
     Bevacizumab - Drug Profile                                                                                  87
          Product Description                                                                                    87
          Mechanism of Action                                                                                    87
          R&D Progress                                                                                           87
     Visudyne + Lucentis - Drug Profile                                                                          88
          Product Description                                                                                    88
          Mechanism of Action                                                                                    88
          R&D Progress                                                                                           88
     Verteporfin Photodynamic Therapy + Ranibizumab + Triamcinolone - Drug Profile                               90
          Product Description                                                                                    90
          Mechanism of Action                                                                                    90
          R&D Progress                                                                                           90
     Lucentis + Visudyne - Drug Profile                                                                          92
          Product Description                                                                                    92
          Mechanism of Action                                                                                    92
          R&D Progress                                                                                           92
     Lucentis - Drug Profile                                                                                     93
          Product Description                                                                                    93
          Mechanism of Action                                                                                    93
          R&D Progress                                                                                           93
     Avastin - Drug Profile                                                                                      94
          Product Description                                                                                    94
          Mechanism of Action                                                                                    94
          R&D Progress                                                                                           94
     Verteporfin + Triamcinolone - Drug Profile                                                                  95




Age Related Macular Degeneration – Pipeline Review, Q2 2011                               GMDHC1073IDB / Pub April 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                         Page(4)
Age Related Macular Degeneration – Pipeline Review, Q2 2011


          Product Description                                                                                                               95
          Mechanism of Action                                                                                                               95
          R&D Progress                                                                                                                      95
     Verteporfin + Pegaptanib - Drug Profile                                                                                                96
          Product Description                                                                                                               96
          Mechanism of Action                                                                                                               96
          R&D Progress                                                                                                                      96
     Bevacizumab - Drug Profile                                                                                                             97
          Product Description                                                                                                               97
          Mechanism of Action                                                                                                               97
          R&D Progress                                                                                                                      97
     Verteporfin Photodynamic Therapy + Triamcinolone - Drug Profile                                                                        98
          Product Description                                                                                                               98
          Mechanism of Action                                                                                                               98
          R&D Progress                                                                                                                      98
Age Related Macular Degeneration Therapeutics – Drug Profile Updates                                                                       100
Age Related Macular Degeneration Therapeutics - Discontinued Products                                                                      103
     Age Related Macular Degeneration - Featured News                                                                                      104
          Apr 07, 2011: Lpath Initiates Enrollment Of iSONEP Phase Ib/IIa Proof-of-Concept Trial                                           104
          Apr 05, 2011: Neurotech's NT-501 Implant Slows Vision Loss In Patients With Geographic Atrophy Associated With Dry AMD As Reported
          In PNAS                                                                                                                        104
          Mar 01, 2011: Paloma Pharmaceuticals Provides Update On Ocular Clinical And Oncology Programs                                    105
          Feb 22, 2011: Regeneron Submits Biologics License Application To FDA For VEGF Trap-Eye For Treatment Of Wet Age-Related Macular
          Degeneration                                                                                                                106
          Jan 03, 2011: ACT Receives FDA Clearance For Clinical Trials Using Embryonic Stem Cells To Treat Age-Related Macular Degeneration
                                                                                                                                         107
          Nov 30, 2010: Advanced Cell Technology Files IND With FDA For Phase I/II Clinical Trial Using Embryonic Stem Cells To Treat Dry AMD
                                                                                                                                            108
          Nov 22, 2010: Bayer And Regeneron Report Positive Results From Two Phase III Studies With VEGF Trap-Eye In Wet Age-related
          Macular Degeneration                                                                                                             108
          Nov 10, 2010: ChemoCentryx Presents Positive Phase I Results For CCX168 At Annual American College Of Rheumatology Meeting 110
          Nov 09, 2010: Oxford BioMedica Receives FDA IND Approval For RetinoStat In Wet Age-Related Macular Degeneration                  111
          Oct 18, 2010: Phase IIb Data Suggest ReVision’s Oral Fenretinide (RT-101) Slows Lesion Growth, Preserves Vision and Reduces
          Incidence of Neovascularization in Geographic Atrophy Patients                                                                   112
Appendix                                                                                                                                   113
     Methodology                                                                                                                           113
          Coverage                                                                                                                         113
          Secondary Research                                                                                                               113
          Primary Research                                                                                                                 113
          Expert Panel Validation                                                                                                          114
     Contact Us                                                                                                                            114
     Disclaimer                                                                                                                            114




Age Related Macular Degeneration – Pipeline Review, Q2 2011                                                GMDHC1073IDB / Pub April 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                    Page(5)
Age Related Macular Degeneration – Pipeline Review, Q2 2011




Lis t o f Ta b le s
Number of Products Under Development for Age Related Macular Degeneration, Q2 2011                                       12

Products under Development for Age Related Macular Degeneration – Comparative Analysis, Q2 2011                          13

Number of Products under Development by Companies, Q2 2011                                                               15

Number of Products under Development by Companies, Q2 2011                                                               16

Number of Products under Development by Companies, Q2 2011                                                               17

Number of Products under Development by Companies, Q2 2011                                                               18

Number of Products under Investigation by Universities/Institutes, Q2 2011                                               20

Number of Products under Investigation by Universities/Institutes, Q2 2011                                               21

Comparative Analysis by Late Stage Development, Q2 2011                                                                  22

Comparative Analysis by Mid Clinical Stage Development, Q2 2011                                                          23

Comparative Analysis by Early Clinical Stage Development, Q2 2011                                                        24

Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q2 2011                                            25

Products under Development by Companies, Q2 2011                                                                         26

Products under Development by Companies, Q2 2011                                                                         27

Products under Development by Companies, Q2 2011                                                                         28

Products under Development by Companies, Q2 2011                                                                         29

Products under Development by Companies, Q2 2011                                                                         30

Products under Development by Companies, Q2 2011                                                                         31

Products under Development by Companies, Q2 2011                                                                         32

Products under Development by Companies, Q2 2011                                                                         33

Alcon, Inc., 2011                                                                                                        36

Genzyme Corporation, 2011                                                                                                36

Johnson & Johnson, 2011                                                                                                  37

F. Hoffmann-La Roche Ltd., 2011                                                                                          37

Abbott Laboratories, 2011                                                                                                38

Allergan, Inc., 2011                                                                                                     38

QLT Inc., 2011                                                                                                           39

Advanced Cell Technology, Inc., 2011                                                                                     39

GlaxoSmithKline plc, 2011                                                                                                40

Santen Pharmaceutical Co., Ltd., 2011                                                                                    40

Oxford BioMedica plc, 2011                                                                                               41

Lux Biosciences, Inc., 2011                                                                                              
								
To top